Voltar
Artigo Acesso aberto Revisado por pares
BIBTEX RIS

Journey of a hematopoietic stem cell transplantation center through COVID-19 pandemic: one-year experience

2022; Hamburg University Press; Volume: 10; Issue: 3-4 Linguagem: Inglês

10.18620/ctt-1866-8836-2021-10-3-4-30-37

ISSN

1867-416X

Autores

Aleksandr Siniaev, Marina Popova, Yulia A. Rogacheva, Anna Spiridonova, Maria U. Averyanova, Alexander L. Alyanskiy, Bella Ayubova, Elena V. Babenko, Evgenii Bakin, Ildar Barkhatov, Maxim Pavlovich Bogomolny, Т. А. Быкова, A. A. Vitrischak, M. D. Vladovskaya, Yulia Vlasova, Alisa Alisa, Asmik Gevorgian, Tatiana Gindina, Oleg V. Goloshchapov, К. А. Екушов, М. А. Эстрина, Н. Е. Иванова, M. A. Kucher, Alexei B. Chukhlovin, Kirill V. Lepik, Inna V. Markova, N. Mikhailova, Elena Morozova, Anna A. Osipova, О. В. Паина, Dmitrii Pevtsov, Anna G. Smirnova, Alexandr Shvetsov, Lilia Stelmakh, Galina Stolbenko, L. S. Zubarovskaya, Sergey N. Bondarenko, Ivan Moiseev, Alexander Kulagin,

Tópico(s)

COVID-19 and healthcare impacts

Resumo

Hematopoietic stem cell transplantation (HSCT) is a life-saving procedure for oncological, hematological and non-malignant disorders.Despite global trend for a decrease of transplantation activity in view of the COVID-19 pandemic, we tried to maintain it by taking preventive measures and optimizing infection control in our center.

Referência(s)